1. Home
  2. TECX vs AVIR Comparison

TECX vs AVIR Comparison

Compare TECX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • AVIR
  • Stock Information
  • Founded
  • TECX 2019
  • AVIR 2012
  • Country
  • TECX United States
  • AVIR United States
  • Employees
  • TECX N/A
  • AVIR N/A
  • Industry
  • TECX
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • TECX
  • AVIR Health Care
  • Exchange
  • TECX Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • TECX 334.4M
  • AVIR 275.6M
  • IPO Year
  • TECX 2018
  • AVIR 2020
  • Fundamental
  • Price
  • TECX $19.81
  • AVIR $3.25
  • Analyst Decision
  • TECX Buy
  • AVIR Hold
  • Analyst Count
  • TECX 7
  • AVIR 1
  • Target Price
  • TECX $78.67
  • AVIR $6.00
  • AVG Volume (30 Days)
  • TECX 156.7K
  • AVIR 402.4K
  • Earning Date
  • TECX 08-13-2025
  • AVIR 08-06-2025
  • Dividend Yield
  • TECX N/A
  • AVIR N/A
  • EPS Growth
  • TECX N/A
  • AVIR N/A
  • EPS
  • TECX N/A
  • AVIR N/A
  • Revenue
  • TECX N/A
  • AVIR N/A
  • Revenue This Year
  • TECX N/A
  • AVIR N/A
  • Revenue Next Year
  • TECX N/A
  • AVIR N/A
  • P/E Ratio
  • TECX N/A
  • AVIR N/A
  • Revenue Growth
  • TECX N/A
  • AVIR N/A
  • 52 Week Low
  • TECX $13.70
  • AVIR $2.46
  • 52 Week High
  • TECX $61.07
  • AVIR $4.15
  • Technical
  • Relative Strength Index (RSI)
  • TECX 40.56
  • AVIR 63.83
  • Support Level
  • TECX $22.13
  • AVIR $3.15
  • Resistance Level
  • TECX $25.75
  • AVIR $3.35
  • Average True Range (ATR)
  • TECX 1.44
  • AVIR 0.13
  • MACD
  • TECX -0.48
  • AVIR 0.00
  • Stochastic Oscillator
  • TECX 10.68
  • AVIR 73.24

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: